Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eculizumab may prevent leukemia and stop the destruction of red blood cells in patients with paroxysmal nocturnal hemoglobinuria. PURPOSE: This randomized phase III trial is studying how well eculizumab works in treating patients with paroxysmal nocturnal hemoglobinuria.

Timeline

Start

2004-11

Primary completion

—

Completion

2005-06

Drugs

Indications